NASDAQ:ABLXABLYNX NV/ADR Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ABLYNX NV/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume249,005 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileInstitutional OwnershipHeadlinesOptions ChainSocial Media Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for ABLYNX NV/ADR. Previous Next 2.5 Community Rank Outperform VotesABLYNX NV/ADR has received 125 “outperform” votes. (Add your “outperform” vote.)Underperform VotesABLYNX NV/ADR has received 130 “underperform” votes. (Add your “underperform” vote.)Community SentimentABLYNX NV/ADR has received 50.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ABLYNX NV/ADR and other stocks. Vote “Outperform” if you believe ABLX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABLX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldABLYNX NV/ADR does not currently pay a dividend.Dividend GrowthABLYNX NV/ADR does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ABLYNX NV/ADR insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABLX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.ablynx.com/ PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Receive ABLX News and Ratings via Email Sign-up to receive the latest news and ratings for ABLX and its competitors with MarketBeat's FREE daily newsletter. ABLYNX NV/ADR (NASDAQ:ABLX) Frequently Asked Questions Has ABLYNX NV/ADR been receiving favorable news coverage? Press coverage about ABLX stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ABLYNX NV/ADR earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutABLYNX NV/ADR. Who are some of ABLYNX NV/ADR's key competitors? Some companies that are related to ABLYNX NV/ADR include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF) and Cardiome Pharma (COM). What other stocks do shareholders of ABLYNX NV/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other ABLYNX NV/ADR investors own include GALAPAGOS NV/S (GLPG), Gilead Sciences (GILD), Ablynx (ABLYF), argenx (ARGX), AbbVie (ABBV), Maya Gold & Silver (MYA), Airbus (AIR), China New Energy (CNEL), Acorda Therapeutics (ACOR) and ADMA Biologics (ADMA). Who are ABLYNX NV/ADR's key executives? ABLYNX NV/ADR's management team includes the following people: Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)Mr. Wim Ottevaere, Chief Financial Officer (Age 62)Mr. Piet Houwen, Chief Operations OfficerDr. Robert Friesen Ph.D., Chief Scientific OfficerLies Vanneste, Director of Investor Relations When did ABLYNX NV/ADR IPO? (ABLX) raised $151 million in an initial public offering on Wednesday, October 25th 2017. The company issued 7,200,000 shares at $20.95 per share. BofA Merrill Lynch, J.P. Morgan and Jefferies served as the underwriters for the IPO and Baird, Bryan, Garnier and Ladenburg Thalmann were co-managers. What is ABLYNX NV/ADR's stock symbol? ABLYNX NV/ADR trades on the NASDAQ under the ticker symbol "ABLX." What is ABLYNX NV/ADR's official website? The official website for ABLYNX NV/ADR is http://www.ablynx.com/. This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: How is a buy-side analyst different from a sell-side analyst?